

# Zoe K Mcquilten

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/2250084/zoe-k-mcquilten-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

96  
papers

1,562  
citations

22  
h-index

37  
g-index

107  
ext. papers

2,253  
ext. citations

4.9  
avg, IF

5  
L-index

#	Paper	IF	Citations
96	Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1858-1867	59.2	107
95	Predictive factors of bleeding events in adults undergoing extracorporeal membrane oxygenation. <i>Annals of Intensive Care</i> , <b>2016</b> , 6, 97	8.9	103
94	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2020</b> , 7, CD013600	5.2	100
93	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. <i>The Cochrane Library</i> , <b>2020</b> , 5, CD013600	5.2	85
92	Fibrinogen is an independent predictor of mortality in major trauma patients: A five-year statewide cohort study. <i>Injury</i> , <b>2017</b> , 48, 1074-1081	2.5	69
91	Haemostasis and innate immunity - a complementary relationship: A review of the intricate relationship between coagulation and complement pathways. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 782-798	4.5	69
90	Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. <i>Medical Journal of Australia</i> , <b>2020</b> , 212, 481-489	4	66
89	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2020</b> , 10, CD013600	5.2	64
88	Optimal Dose, Timing and Ratio of Blood Products in Massive Transfusion: Results from a Systematic Review. <i>Transfusion Medicine Reviews</i> , <b>2018</b> , 32, 6-15	7.4	49
87	Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. <i>The Cochrane Library</i> , <b>2021</b> , 5, CD013600	5.2	45
86	Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion. <i>Vox Sanguinis</i> , <b>2014</b> , 107, 60-70	3.1	44
85	SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. <i>The Cochrane Library</i> , <b>2021</b> , 9, CD013825	5.2	39
84	Transfusion interventions in critical bleeding requiring massive transfusion: a systematic review. <i>Transfusion Medicine Reviews</i> , <b>2015</b> , 29, 127-37	7.4	37
83	Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 1690-1702	27.4	37
82	Underestimation of myelodysplastic syndrome incidence by cancer registries: Results from a population-based data linkage study. <i>Cancer</i> , <b>2014</b> , 120, 1686-94	6.4	33
81	Fibrinogen concentration and use of fibrinogen supplementation with cryoprecipitate in patients with critical bleeding receiving massive transfusion: a bi-national cohort study. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 131-141	4.5	33
80	Off-label use of recombinant factor VIIa in pediatric patients. <i>Pediatrics</i> , <b>2012</b> , 129, e1533-40	7.4	29

79	Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. <i>Transfusion Medicine Reviews</i> , <b>2018</b> , 32, 77-88	7.4	28
78	Transfusion practice varies widely in cardiac surgery: Results from a national registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2014</b> , 147, 1684-1690.e1	1.5	28
77	Is platelet transfusion associated with hospital-acquired infections in critically ill patients?. <i>Critical Care</i> , <b>2017</b> , 21, 2	10.8	26
76	Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. <i>Vox Sanguinis</i> , <b>2017</b> , 112, 240-248	3.1	25
75	Emerging Infectious Diseases and Blood Safety: Modeling the Transfusion-Transmission Risk. <i>Transfusion Medicine Reviews</i> , <b>2017</b> , 31, 154-164	7.4	22
74	Myeloma in the Real World: What Is Really Happening?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 133-144.e1	2	22
73	Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 279-290	4.5	22
72	The Australian and New Zealand Haemostasis Registry: ten years of data on off-licence use of recombinant activated factor VII. <i>Blood Transfusion</i> , <b>2015</b> , 13, 86-99	3.6	22
71	Low-Dose Versus Therapeutic Anticoagulation in Patients on Extracorporeal Membrane Oxygenation: A Pilot Randomized Trial. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e563-e571	1.4	21
70	Platelet storage duration and its clinical and transfusion outcomes: a systematic review. <i>Critical Care</i> , <b>2018</b> , 22, 185	10.8	20
69	Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. <i>Cancer</i> , <b>2015</b> , 121, 2892-9	6.4	20
68	Intravenous immunoglobulin in critically ill adults: When and what is the evidence?. <i>Journal of Critical Care</i> , <b>2015</b> , 30, 652.e9-16	4	18
67	Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. <i>Transfusion</i> , <b>2013</b> , 53, 1714-21	2.9	16
66	Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 88-98	3.1	16
65	How should we use convalescent plasma therapies for the management of COVID-19?. <i>Blood</i> , <b>2021</b> , 137, 1573-1581	2.2	16
64	Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. <i>BMC Medical Research Methodology</i> , <b>2016</b> , 16, 151	4.7	14
63	Duration of red blood cells storage and outcome in critically ill patients. <i>Journal of Critical Care</i> , <b>2014</b> , 29, 476.e1-8	4	13
62	Hospital blood bank information systems accurately reflect patient transfusion: results of a validation study. <i>Transfusion</i> , <b>2011</b> , 51, 943-8	2.9	13

61	The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial. <i>Trials</i> , <b>2019</b> , 20, 592	2.8	12
60	Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. <i>BMC Infectious Diseases</i> , <b>2021</b> , 21, 1170 <sup>4</sup>		11
59	Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. <i>Internal Medicine Journal</i> , <b>2017</b> , 47, 695-698	1.6	10
58	Massive transfusions for critical bleeding: is everything old new again?. <i>Transfusion Medicine</i> , <b>2018</b> , 28, 140-149	1.3	10
57	Infection is an Independent Predictor of Death in Diffuse Large B Cell Lymphoma. <i>Scientific Reports</i> , <b>2017</b> , 7, 4395	4.9	10
56	Contemporary management of neonatal alloimmune thrombocytopenia: good outcomes in the intravenous immunoglobulin era: results from the Australian neonatal alloimmune thrombocytopenia registry. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , <b>2017</b> , 30, 2488-2494	2	8
55	Introduction of universal prestorage leukodepletion of blood components, and outcomes in transfused cardiac surgery patients. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2015</b> , 150, 216-22	1.5	8
54	Outpatient transfusions for myelodysplastic syndromes. <i>Hematology American Society of Hematology Education Program</i> , <b>2020</b> , 2020, 167-174	3.1	8
53	Impact of patient blood management guidelines on blood transfusions and patient outcomes during cardiac surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , <b>2020</b> , 160, 437-445.e20	1.5	8
52	Improving outcomes for hospital patients with critical bleeding requiring massive transfusion: the Australian and New Zealand Massive Transfusion Registry study methodology. <i>BMC Research Notes</i> , <b>2016</b> , 9, 457	2.3	8
51	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. <i>EBioMedicine</i> , <b>2021</b> , 74, 103729	8.8	7
50	Revisiting acquired aplastic anaemia: current concepts in diagnosis and management. <i>Internal Medicine Journal</i> , <b>2019</b> , 49, 152-159	1.6	7
49	Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, e415-e424	2	6
48	Platelet transfusion is not associated with increased mortality or morbidity in patients undergoing cardiac surgery. <i>Transfusion</i> , <b>2018</b> , 58, 1218-1227	2.9	6
47	A time-driven, activity-based costing methodology for determining the costs of red blood cell transfusion in patients with beta thalassaemia major. <i>Transfusion Medicine</i> , <b>2019</b> , 29, 33-40	1.3	6
46	Evaluation of clinical coding data to determine causes of critical bleeding in patients receiving massive transfusion: a bi-national, multicentre, cross-sectional study. <i>Transfusion Medicine</i> , <b>2017</b> , 27, 114-121	1.3	5
45	Is Platelet Expiring Out of Date? A Systematic Review. <i>Transfusion Medicine Reviews</i> , <b>2020</b> , 34, 42-50	7.4	5
44	The cost of blood: a study of the total cost of red blood cell transfusion in patients with $\beta$ thalassaemia using time-driven activity-based costing. <i>Transfusion</i> , <b>2019</b> , 59, 3386-3395	2.9	4

43	Major haemorrhage fatalities in the Australian national coronial database. <i>EMA - Emergency Medicine Australasia</i> , <b>2018</b> , 30, 382-388	1.5	4
42	Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2019</b> , 45, 187-195	5.3	3
41	Haematological features, transfusion management and outcomes of massive obstetric haemorrhage: findings from the Australian and New Zealand Massive Transfusion Registry. <i>British Journal of Haematology</i> , <b>2020</b> , 190, 618-628	4.5	3
40	Anticoagulation in COVID-19.. <i>Lancet, The</i> , <b>2021</b> ,	4.0	3
39	Tissue-Type Plasminogen Activator and Tenecteplase-Mediated Increase in Blood Brain Barrier Permeability Involves Cell Intrinsic Complement. <i>Frontiers in Neurology</i> , <b>2020</b> , 11, 577272	4.1	3
38	Transfusion of stored platelets: balancing risks and product availability. <i>International Journal of Clinical Transfusion Medicine</i> , <b>2016</b> , Volume 4, 133-138	0.8	3
37	A randomised controlled trial of standard transfusion versus fresher red blood cell use in intensive care (TRANSFUSE): protocol and statistical analysis plan. <i>Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine</i> , <b>2014</b> , 16, 255-61	2.8	3
36	Factors Leading to Health Care Exclusion among African Refugees in Australia: The Case of Blood Donation. <i>Journal of Public Policy and Marketing</i> , <b>2017</b> ,	3.8	2
35	Monosomal Karyotype Is Associated With Worse Survival Independent Of Complex Karyotype In Patients With Myelodysplastic Syndrome. <i>Blood</i> , <b>2013</b> , 122, 1523-1523	2.2	2
34	Preoperative identification of cardiac surgery patients at risk of receiving a platelet transfusion: The Australian Cardiac Surgery Platelet Transfusion (ACSePT) risk prediction tool. <i>Transfusion</i> , <b>2020</b> , 60, 2272-2283	2.9	2
33	The Myeloma Landscape in Australia and New Zealand: The First 8 Years of the Myeloma and Related Diseases Registry (MRDR). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e510-e520	2	2
32	Fresh Red Cells for Transfusion in Critically Ill Adults: An Economic Evaluation of the Standard Issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) Clinical Trial. <i>Critical Care Medicine</i> , <b>2019</b> , 47, e572-e579	1.4	2
31	Vox Sanguinis International Forum on Hospital Transfusion Services Response to COVID-19: Responses. <i>Vox Sanguinis</i> , <b>2020</b> , 115, e1-e17	3.1	1
30	Patient-reported outcome measures in multiple myeloma: Real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. <i>American Journal of Hematology</i> , <b>2020</b> , 95, E178-E187	7.1	1
29	Clinical coding data algorithm to categorize type of gastrointestinal bleeding as a primary reason for massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry. <i>Vox Sanguinis</i> , <b>2019</b> , 114, 853-860	3.1	1
28	A dynamic mathematical model of red blood cell clinical demand to assess the impact of prolonged blood shortages and transfusion restriction policies. <i>Transfusion</i> , <b>2014</b> , 54, 2705-15	2.9	1
27	Blood donation by African migrants and refugees in Australia. <i>ISBT Science Series</i> , <b>2015</b> , 10, 257-262	1.1	1
26	A systematic review and network meta-analysis of incentive- and non-incentive-based interventions for increasing blood donations. <i>Vox Sanguinis</i> , <b>2020</b> , 115, 275-287	3.1	1

25	Recombinant Activated Factor VII for Bleeding In the Setting of Malignancy or Hematopoietic Stem Cell Transplantation: The Australian and New Zealand Experience, 2000-2009. <i>Blood</i> , <b>2011</b> , 118, 3311-3317	2.2	1
24	Introduction Of Universal Leucodepletion Associated With a Reduction In New Renal Failure, But Not Infection Or Mortality, In Cardiac Surgery Patients: Results From a Before and After Study. <i>Blood</i> , <b>2013</b> , 122, 788-788	2.2	1
23	The role of the transfusion practitioner in the management of anaemia. <i>ISBT Science Series</i> , <b>2020</b> , 15, 82-90	1.1	1
22	Critical peptic ulcer bleeding requiring massive blood transfusion: outcomes of 270 cases. <i>Internal Medicine Journal</i> , <b>2020</b> ,	1.6	1
21	Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2533-2543	4.4	1
20	Fibrinogen in traumatic haemorrhage. <i>Current Opinion in Anaesthesiology</i> , <b>2021</b> , 34, 514-520	2.9	1
19	Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. <i>Transfusion Medicine Reviews</i> , <b>2021</b> , 35, 73-79	7.4	1
18	SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. <i>The Cochrane Library</i> , <b>2022</b> , 2022,	5.2	1
17	Immunological markers for prognostication in cytogenetically normal acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2015</b> , 90, E219-20	7.1	0
16	The Impact of S-Li-M Criteria in Myeloma in a Real-Life Population: Patient & Disease Characteristics, Treatment and Outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). <i>Blood</i> , <b>2020</b> , 136, 30-31	2.2	0
15	Modeling the West Nile virus transfusion transmission risk in a nonoutbreak country associated with traveling donors. <i>Transfusion</i> , <b>2020</b> , 60, 2611-2621	2.9	0
14	Red cell transfusions: Is less always best?: How confident are we that restrictive transfusion strategies should be the standard of care default transfusion practice?. <i>Transfusion</i> , <b>2021</b> , 61, 2195-2203	2.9	0
13	Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. <i>European Journal of Haematology</i> , <b>2021</b> , 107, 497-499	3.8	0
12	Is there an optimal trade-off between anaemia and red blood cell transfusion in surgical critically ill patients after oncologic surgery?. <i>Vox Sanguinis</i> , <b>2021</b> , 116, 808-820	3.1	0
11	Economic Evaluation of National Patient Blood Management Clinical Guidelines in Cardiac Surgery.. <i>Value in Health</i> , <b>2022</b> , 25, 419-426	3.3	0
10	Rationale and design of the intravenous iron for treatment of anemia before cardiac surgery trial. <i>American Heart Journal</i> , <b>2021</b> , 239, 64-72	4.9	0
9	Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia.. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	0
8	Day or overnight transfusion in critically ill patients: does it matter?. <i>Vox Sanguinis</i> , <b>2018</b> , 113, 275-282	3.1	

- 7 An update on indications for platelet transfusion. *ISBT Science Series*, **2016**, 11, 170-176 1.1
- 6 The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes. *Blood*, **2020**, 136, 30-31 2.2
- 5 Variation in Use of Immunoglobulin and Impact on Survival in Multiple Myeloma: A Report from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). *Blood*, **2021**, 138, 4757-4757<sup>2</sup> 2.2
- 4 The Utility of Radionuclide Ventriculography (RNV) Prior to Anthracycline Chemotherapy in Patients with Acute Myeloid Leukemia: A Retrospective, Single Institution Study.. *Blood*, **2007**, 110, 4369-4369<sup>2</sup> 2.2
- 3 Immunity In Cytogenetically Normal Acute Myeloid Leukemia (iCN-AML). *Blood*, **2013**, 122, 1358-1358 2.2
- 2 Age of red blood cells is not associated with in-hospital mortality in massively transfused patients. *Journal of Trauma and Acute Care Surgery*, **2021**, 91, 279-286 3.3
- 1 Blood Transfusion in Hospitals **2022**, 290-312